Page 26 - Interim Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Feb 03, 2021 Patient recruitment in Part 2 of the COVA Study will begin in most clinical centers in Brazil and the United States Interim Analysis of Part 1 is expected in Q1 2021 Results from the full study (Part 1 and Part 2) are expected in Q2 2021 PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, in...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim ... Cassava Sciences, Inc.February 2, 2021 GMT - Patients’ Cognition Improved 1.6 Points on ADAS-Cog11 - - Patients’ Behavior Improved 1.3 Points on NPI - - Improvements Maintained at 6 Months - - Results Support Advancing Simufilam into Phase 3 Clinical Program - AUSTIN, Texas, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced results of an interim analysis fr...

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months. The interim analysis assessed 468 cases of symptomatic COVID-19 among 44,325 adult volunteers in Argentina, Brazil, Chile, Colombia, Mexic...

Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from full study population of 350 patients and results of second study of KB109 are expected in the first quarter of 2021 LEXINGTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study wer...